Key takeaways
- Approximately 20% of American adults have tried a GLP-1 medication, with 11% currently using one.
- Active GLP-1 usage has grown fourfold over the past two years, driven by new oral pills and wider health indications.
- Health experts warn against telehealth platforms that prescribe GLP-1s within hours based solely on an online questionnaire.
- A safe telehealth provider should require baseline blood work and provide active, long-term clinician oversight.
What happened
A new report from Scripps News highlighting data from U.S. News & World Report reveals that approximately 20% of American adults—or one in five—have now tried a GLP-1 medication. Driven by expanding treatment indications and the arrival of highly anticipated oral pill formulations, active GLP-1 usage has surged fourfold over the last two years, with roughly 11% of the U.S. population currently taking these medications.
Why it matters
This 20% adoption milestone marks a massive shift in how chronic weight management is handled in the United States, transforming GLP-1s from niche, high-cost therapies into mainstream clinical tools. As demand continues to explode, an increasingly crowded online marketplace has emerged, prompting health experts to warn consumers about the risks of low-quality telehealth operations.
For patients looking to navigate this landscape safely, the massive volume of online options means they must learn to distinguish between reputable clinical platforms and "prescription mills." Some telehealth platforms are bypassing critical safety protocols, such as comprehensive medical history reviews, baseline blood work, and ongoing clinician oversight, to ship medications within hours of a patient filling out an online form.
What the data says
The rapid rise of GLP-1 adoption is backed by several key statistics highlighted by Scripps News and U.S. News managing editor of health, Gretel Schueller:
- 1 in 5: The proportion of U.S. adults who have tried a GLP-1 drug.
- 11%: The percentage of the American population currently taking a GLP-1 medication in 2026.
- 400%: The increase in current active users over the last two years.
- 52%: The percentage of health experts who identify GLP-1 expansion as the single largest public health trend of 2026.
- 66%: The share of surveyed GLP-1 patients who reported losing more than 10% of their body weight.
To help consumers find legitimate care, U.S. News evaluated more than 20 telehealth platforms across six key performance areas: clinical support, long-term follow-up, health screening, pricing transparency, insurance navigation support, and patient feedback. The evaluation ultimately approved 11 platforms, intentionally excluding companies that strictly sell compounded GLP-1 therapies, citing concerns over the lack of direct FDA safety reviews, potential contamination, and dosing errors.
Furthermore, experts emphasized that patient safety requires baseline lab work—specifically checking kidney and liver function—prior to starting a prescription. The lack of these baseline labs or any direct, interactive communication with a licensed healthcare professional represents a major clinical red flag.
How it compares
For U.S. buyers, navigating online care involves a stark divide between platforms focusing on brand-name medications and those offering compounded alternatives.
Brand-name GLP-1s like Wegovy, Zepbound, and the newly available oral pill Foundayo carry proven clinical track records but come with steep retail prices, often ranging from $900 to $1,350 per month without insurance. Telehealth providers that deal exclusively in brand-name drugs must provide robust prior authorization and insurance concierge services to help patients secure coverage.
Conversely, compounded semaglutide and tirzepatide are widely available through online clinics for flat cash rates, typically ranging from $200 to $400 per month. While compounded options bypass the high cost of brand-name drugs, they do not undergo the same rigorous FDA review processes. This makes thorough clinical vetting by the provider even more critical. Buyers shopping for GLP-1 telehealth providers should use our detailed guide on /providers and compare platform features directly using our interactive tool on /compare.
How this fits the bigger picture
The explosive growth of the GLP-1 market, especially the fourfold rise in active users, is heavily driven by the diversification of drug formats. The shift from weekly self-injections to daily oral alternatives has removed a significant barrier for many patients. We previously explored this market evolution in our coverage of the FDA approval of the oral Wegovy pill, which opened a completely needle-free path for telehealth buyers.
Furthermore, the expansion of Eli Lilly’s oral weight-loss portfolio, which we analyzed when the UK approved Lilly’s Foundayo pill, highlights how global pharmaceutical giants are rushing to satisfy the exact demand trends identified in the Scripps News report. As more adults seek out these medications, telehealth platforms must balance rapid onboarding with responsible clinical care. Platforms like Found have been recognized for maintaining this balance, as we detailed in our review of how U.S. News rated Found 4.6 stars due to its strong clinical support and comprehensive insurance navigation.
What happens next
As GLP-1 medications expand their therapeutic reach to treat conditions like arthritis, heart disease, kidney disease, and addiction, the clinical protocols required to prescribe them will become more complex. Telehealth platforms will face mounting pressure from regulatory bodies and medical boards to implement stricter screening processes.
Patients should expect top-tier online clinics to increasingly mandate baseline laboratory tests and synchronous video or phone consultations before issuing a prescription. Over the coming year, we expect a widening regulatory gap between high-standard telehealth providers and low-overhead "questionnaire-only" sites as the industry moves to protect patient safety.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional before starting any weight-loss medication or changing your treatment plan.